Karen Malkhasyan, MD

Articles by Karen Malkhasyan, MD

The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy

ByKaren Malkhasyan, MD,Hari A. Deshpande, MD,Adebowale J. Adeniran, MD,John W. Colberg, MD,Daniel P. Petrylak, MD

October 15th 2013

A 55-year-old woman with a history of metastatic melanoma in remission for 8 years presented to the emergency department with gross hematuria. A CT scan, ordered because the patient was in menopause, demonstrated a bladder tumor.

Latest Updated Articles

The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy
Published: October 15th 2013 | Updated:

Karen Malkhasyan, MD

Articles by Karen Malkhasyan, MD

The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy

Latest Updated Articles

Trending on CancerNetwork

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma